antiinflammatory agent 1

Anti-inflammatory agent 1 is a chemical compound designated for reducing inflammation, structurally characterized by a [carboxyl acid], [oxygen], and [hydrocarbon] ring, with notable efficacy in mitigating inflammatory responses.

Anti-inflammatory agent 100 (Compound (+)-4S-23) is an anti-inflammatory compound. It inhibits the MAPK and NF-κB signaling pathways by preventing the phosphorylation of IκB-α and blocking the nuclear translocation of phosphorylated p65. Anti-inflammatory agent 100 also reduces the production of NO (IC50: 0.5 μM) and the secretion of TNF-α, IL-6, and IL-1β.

Anti-inflammatory agent 102 (Compound 11a) is an orally effective anti-inflammatory compound. It exerts its effects by inhibiting the activation of the ASK1/p38 MAPKs/NF-κB signaling pathway. This agent displays significant anti-inflammatory activity by suppressing the release of NO, ROS, and inflammatory cytokines such as IL-6, TNF-α, and IL-1β. Anti-inflammatory agent 102 is applicable in research concerning inflammatory diseases, including ulcerative colitis (UC).

Anti-inflammatory agent 101 (Compound C04) is an orally active anti-inflammatory agent with notable anti-lipid accumulation, anti-inflammatory, and anti-fibrotic properties. It functions by reducing fatty acid uptake, enhancing fatty acid oxidation, and alleviating inflammation, making it applicable in the study of NASH and related liver fibrosis.

Anti-inflammatory agent 104 (Compound 26) is an anti-inflammatory compound. It inhibits TNF-α synthesis and release in the U937 human macrophage cell line with an IC50 of 0.024 nM. Additionally, Anti-inflammatory agent 104 reduces eosinophil levels in rat lungs by 63%.

Anti-inflammatory agent 105 (Compound 12) is an anti-inflammatory compound. It inhibits the synthesis and release of TNF-α in the human macrophage cell line U937, with an IC50 of 0.124 nM.

Anti-inflammatory agent 106 (Example 2) is a derivative of Paeonol with potent anti-inflammatory properties. It effectively inhibits xylene-induced ear swelling in mice and can be utilized for research into inflammatory diseases such as rheumatoid arthritis, psoriasis, and type 1 diabetes.

Anti-inflammatory agent 109 (Compound 2m) is an anti-inflammatory compound. It directly interacts with p65, reducing the abnormal activation of the NF-κB pathway. This agent significantly inhibits the release of key pro-inflammatory mediators, such as IL-1β, COX-2, and iNOS. Additionally, Anti-inflammatory agent 109 offers substantial protection against LPS-induced acute liver injury in septic mice.

Anti-inflammatory agent 107 is an orally effective compound that serves as a potent anti-inflammatory agent. It inhibits NF-κB with a strong binding affinity of -9.4578 kcal/mol. The agent reduces levels of inflammatory markers such as TNF-α, IL-6, INF-γ, NF-κβ, CRP (C-reactive protein), and ESR (Erythrocyte Sedimentation Rate). Additionally, it enhances the activity of endogenous antioxidant systems by increasing SOD (superoxide dismutase), CAT (catalase), and GSH (glutathione). Notably, Anti-inflammatory agent 107 exhibits no hepatic or renal toxicity and provides significant protective effects for the liver and kidneys. It also improves leukocyte infiltration and tissue edema in a dose-dependent manner, making it valuable for anti-inflammatory research.

Anti-inflammatory agent 110 (Compound 7b) is an analgesic/anti-inflammatory compound with strong binding affinity to COX-2. It demonstrates potent analgesic activity in the mouse hot plate test and significant anti-inflammatory effects in the carrageenan-induced edema model in rats.

Anti-inflammatory agent 113 (compound B5) is a cathepsin L (CTSL) inhibitor and anti-inflammatory compound with an IC50 for CTSL of 5.52 μM. It hinders the maturation of CTSL, downregulates the activation of NF-κB and p38 MAPK signaling pathways, and binds stably at the CTSL active site through non-covalent interactions with Asp162, Cys25, and Glu63. This compound also inhibits the production of pro-inflammatory cytokines (IL-6, IL-8), reduces pulmonary infiltration of inflammatory cells, and alleviates lung tissue damage. Anti-inflammatory agent 113 is applicable in research on acute lung injury.

Anti-inflammatory agent 112 (compound 3f) is an inducible nitric oxide synthase (iNOS) inhibitor, cyclooxygenase-2 (COX-2) inhibitor, and anti-inflammatory agent. It suppresses iNOS and COX-2 protein expression, decreases the production of nitric oxide, interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-α), and alleviates lipopolysaccharide (LPS)-induced inflammatory responses. This compound is useful in studying inflammatory diseases.

Anti-inflammatory agent 111 is a potent anti-inflammatory compound. It reduces Lipopolysaccharides (LPS)-induced expression of i-NOS and COX-2 proteins, thereby decreasing the production of nitric oxide, IL-6, and TNF-α. At biologically active concentrations, Anti-inflammatory agent 111 maintains normal cell viability and is applicable for research on inflammation-related diseases.

Anti-inflammatory agent 15 (compound 29) is a potent antimycobacterial agent used in tuberculosis (TB) research, inhibiting the growth of Mtb H37Rv and M299 with MIC50 values of 2.3 and 7.8 μM, respectively. This compound also suppresses the expression of iNOS, thereby inhibiting NO, TNF-α, and IL-1β production [1].

Anti-inflammatory agent 11 (compound 16) is a potent antimycobacterial agent used in tuberculosis (TB) research. It inhibits the growth of Mtb H37Rv and M299 with MIC 50 values of 1.3 and 6.9 μM, respectively. Additionally, it reduces inflammation by suppressing iNOS expression and inhibiting NO, TNF-α, and IL-1β production [1].

Anti-inflammatory agent 14 (compound 28) exhibits a MIC50 of 2 μM for Mtb H37Rv and also functions as an anti-inflammatory agent [1].

Anti-inflammatory agent 17 an orally active anti-inflammatory agent, demonstrates potent efficacy in inhibiting the release of IL-6 and TNF-α without causing cytotoxicity in in vitro experiments. Furthermore, in vivo studies confirm its anti-inflammatory activity. Given its attributes, Compound 17 holds promise for investigating Acute lung injury (ALI) [1].

Anti-inflammatory agent 16 (compound 14) is a potent peptidomimetic that significantly reduces the expression levels of TNFα, NO, CD40, and CD86 [1].

Anti-inflammatory agent 10 is a tilomisole-based benzimidazole-thiazole derivative that is orally active. anti-inflammatory agent 10 is more active against COX-2 enzymes than COX-1.

Anti-inflammatory agent 13 is a pentacyclic triterpene compound with a significant inhibitory effect on inflammation models. anti-inflammatory agent 13 has the potential to be used in studies of DAMP or PAMP-induced inflammation.

Anti-inflammatory agent 12 is a pentacyclic triterpene compound that showed a significant bias in LPS-induced inflammatory responses (IC50: 2.22 μM). anti-inflammatory agent 12 has potential for use in inflammatory disease research.

Anti-inflammatory agent 18 inhibits NO activity (IC50: 15.94 μM) and has an inhibitory effect on the late inflammatory response induced by HMGB1 and can be used to study late inflammatory diseases such as coronavirus disease (COVID-19), sepsis, etc.

Anti-inflammatory agent 19 inhibits NO (IC50: 36.00 μM). anti-inflammatory agent 19 exhibits an inhibitory effect on HMGB1-induced late inflammatory responses. anti-inflammatory agent 19 can be used to study late inflammatory diseases such as Coronavirus disease (COVID-19), sepsis, etc.

Meloxicam-D3 is deuterium labeled Meloxicam. Meloxicam (T0826) is a non-steroidal antiinflammatory agent, inhibits COX activity, (Target:COX-1; IC50: 36.6 μM ; (Target:COX-2; IC50: 0.49 μM).